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Summary The potential of cis-diamminedichloroplatinum(II) (CDDP), trans-di(2-nitroimidazole)dichloro-
platinum(II) (NIPt), trans-di(2-amino-5-nitrothiazole)dichloroplatinum(II) (Plant), cis-(1,2-diamino-4-nitro-
benzene)dichloroplatinum(II) (Plato), and cis-di-pyridinedichloroplatinum(II) (PyPt) to act as chemosensitizers
of mitomycin C cytotoxicity toward EMT6 cells under oxygenated and hypoxic conditions has been assessed.
Cells were given a 1 h treatment with the platinum complex under oxygenated or hypoxic conditions and then
an additional one hour of exposure to the combination. Two concentrations of each platinum complex, 0.1
and 0.01 LM, were tested in combination with mitomycin C at 1, 0.1 and 0.01 Mm. The results were analyzed
via isobolograms. Under oxygenated conditions the combinations of the various platinum complexes and
mitomycin C produced approximately a 2-3-fold enhancement in cell killing. Under hypoxic conditions
enhancements of 5-fold, 20-fold and 60-fold were obtained with CDDP and 1, 0.1 and 0.01 Mm mitomycin C,
respectively. The combinations of 0.1 gM NIPT and mitomycin C under hypoxic conditions were 30-60-fold
more cytotoxic than expected by additivity. With 0.01Mm NIPT a 15-23-fold enhancement of mitomycin C
cytotoxicity was observed. The Plant-mitomycin C combinations produced a 5-14-fold enhancement in cell
killing under hypoxic conditions. Under hypoxic conditions the combinations of 0.1 gM Plato and mitomycin
C were 30-60-fold more cytotoxic than expected. At 0.01yM Plato an 8-16-fold enhancement in cytotoxicity
was observed under hypoxic conditions. PyPt and mitomycin C produced an 8-14-fold enhancement in
cytotoxicity under hypoxic conditions. Overall, the platinum complexes containing radiosensitizing
nitroaromatic groups were no more active in producing enhanced effects than cis-diamminedichloro-
platinum(II).
One of the limitations in the treatment of solid
tumours is the resistance of hypoxic cells to
radiation therapy and to many chemotherapeutic
agents. Although a variety of methods have been
employed to overcome the hypoxic cell problem,
none has found acceptance as a routinely useful
clinical tool. There is considerable potential in
combined modality treatments and in combination
chemotherapy treatments for drugs which are
selectively toxic toward hypoxic cells.
The selective cytotoxicity toward hypoxic cells in
vitro of mitomycin C, an alkylating agent that is
thought to require reduction of its quinone moiety
for biological activity in an hypoxic environment, is
well established (Crooke & Bradner, 1976; Kennedy
et al., 1980; Rauth et al., 1983; Rockwell, 1982;
Rockwell & Kennedy, 1979; Teicher et al., 1981).
One barrier to demonstrating this effect in vivo is
the cytotoxicity of this drug to normally
oxygenated cells, and it has been reported that
mitomycin C has at most a minor specificity for
hypoxic cells in vivo (Rauth et al., 1983).
Cis-diamminedichloroplatinum(II) and several
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platinum analogs can potentiate the cytotoxic
effects of X-irradiation in cultured cells and in
animal tumour systems (Douple & Richmond,
1979; Douple & Richmond, 1980; Nias & Szuniel,
1977; Overgaard & Khan, 1981). Cis-diammine-
dichloroplatinum(II) has also been shown to
potentiate the effects of several chemotherapeutic
agents including 5-fluorouracil, adriamycin, cyclo-
phosphamide, VP-16-213 and 5-aza-2-deoxycytidine
in L1210 leukaemia (Schabel et al., 1979; Vesely,
1982). The first in vivo demonstrations of enhanced
tumouricidal effects resulting from the combined
treatments of radiosensitizers and chemotherapy
were reported in 1980 by Clement et al. (1980) and
Rose et al. (1980) using in vivo-in vitro cloning or
in situ tumour regrowth assays and could result in
enhancement ratios of up to 2.5. Since those initial
observations a variety of combinations of chemo-
therapeutic agents and sensitizers have been tested
in different animal tumours and tissue culture
systems (Millar, 1982; Sieman, 1982).
This report describes the chemopotentiation of
mitomycin C cytotoxicity toward EMT6 cells in
vitro under oxygenated and hypoxic conditions by
cis-diamminedichloroplatinum(II) and four other
platinum complexes, three of which bear organic
ligands that are also hypoxic cell radiosensitizers.
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Materials and methods
Drugs
Trans-di(2-nitroimidazole)dichloroplatinum(II), trans-
di(2-amino-5-nitrothiazole)dichloroplatinum(II),
cis(l, 2-diamino-4-nitrobenzene)dichloroplatinum(II)
and cis-dipyridinedichloroplatinum(II) were pre-
pared in our laboratory by reaction of a stoichio-
metric amount of the organic ligand with
potassium tetrachloroplatinate (gift of Johnson
Matthey, Inc., Malvern, PA, USA), and
characterized by elemental analysis (Galbraith
Laboratories Inc., Knoxville, TN, USA), and
infrared and ultraviolet spectroscopy. Yields for the
synthetic reaction ranged from 40 to 80%. The
compounds were pure to within +0.2% for carbon,
hydrogen, nitrogen and platinum. Cis-diammine-
dichloroplatinum(II) was a gift from Bristol-Myers
Laboratories, Syracuse, NY USA. The drugs were
prepared in phosphate buffered normal saline. The
new complexes are moderately soluble in aqueous
systems.
Cell culture
The EMT6 mammary tumour cell line is well-
established and has been used widely for the study
of hypoxic cells. EMT6 cells grow as monolayers in
Waymouth's medium supplemented with antibiotics
and 15% newborn calf serum. This cell line has a
doubling time of 16-19h (Rockwell et al., 1972).
The plating efficiency for untreated EMT6 cells is
65-80%. These cells begin to show a measurable
reduction in survival from hypoxic stress alone after
approximately 8-9h in a hypoxic atmosphere
(Rockwell & Kallman, 1973; Teicher et al., 1981;
Teicher & Sartorelli, 1981). For cloning, EMT6
cells are suspended by trypsinization, diluted in
complete growth medium, and a known number of
cells are plated into replicate 60 x 15mm tissue
culture dishes containing 5ml of complete growth
medium. Colonies grow to a countable size in 10-
12 days (Rockwell, 1977; Rockwell, 1978; Teicher &
Sartorelli, 1981) and are visualized by staining with
crystal violet in methanol containing 10%
formaldehyde. The colonies are counted manually.
Each experiment was repeated three times.
Cell survival under oxygenated and hypoxic
conditions
For all experiments cell number was determined
with an electronic particle counter (Coulter
Electronics, Hialeah, FLA, USA); and
asynchronous populations of cells in exponential
growth were used. To produce hypoxia, flasks
containing the cells in complete medium plus serum
were fitted with sterile rubber sleeve serum stoppers
and exposed to a continuously flowing 95%
nitrogen/5% CO2 humidified atmosphere for 5h at
37°C (Teicher et al., 1981). Parallel flasks are
maintained in 95% air/5% CO2. The drug(s), or
vehicle were added to the flasks by injection
through the rubber stopper without disturbing the
hypoxia. The cells were exposed to the platinum
complex at 0.1 or 0.01/IM for 1 h, then mitomycin
C (1, 0.1 or 0.01I M) was added and the cells were
exposed to the drug combination for an additional
hour under oxygenated or hypoxic conditions. The
cells were then suspended and cloned as described
above.
Data analysis
Using the method of Deen and Williams (1979),
isobolograms were generated for the special case in
which the dose of one agent is held constant. This
method produces envelopes of additive effect for
different levels of the variable agent. This is
conceptually identical to generating a series of
isobolograms and replotting the results at a
constant dose of one agent on a log effect by dose
of the second agent coordinate system. Complete
dose response curves for EMT6 cells under
oxygenated and hypoxic conditions with mitomycin
C, CDDP, and each of the platinum complexes
alone were first generated; some of these have been
reported previously (Teicher et al., 1981). The
envelopes of additivity shown in the figures were
generated from a series of iso-effect curves derived
from the complete dose reponse curves for each
agent alone.
Overall, combinations that produce the desired
effect that are within the boundaries of mode I
(solid line in figures) and mode II (dotted line in
figures) are considered additive. Those displaced to
the left are supra-additive while those displaced to
the right are sub-additive (Steel & Peckham, 1979;
Berenbaum, 1977).
As indicated above, this general approach can be
extrapolated to the special case in which the level of
an agent is held constant. Under these conditions
an isobologram can be derived that plots the
expected effect (mode I and mode II) for any level
of the variable agent plus the constant agent
combinations (Dewey et al., 1971). Experimentally,
this approach is far simpler and readily facilitates
determination of additive and non-additive com-
binations.
To facilitate these analyses a flexible interactive
computer program in Basic was written for the
Apple II+ microcomputer. The program first
derives the best fitting dose-response curves using
dose or log dose, and effect, log effect, probit
percent effect, of logit percent effect relations. For
cell survival dose-reponse curves correlations ofCHEMOPOTENTIATION BY PLATINUM COMPLEXES 835
0.96 or greater have been obtained. The program
then calculates isobologram at a constant level of
the selected agent, and plots the data. The figures
show log survival versus dose on a linear scale.
The terms x-fold enhancement and x-fold
potentiation are defined as: surviving fraction of
mitomycin C+Pt complex calculated as mode II
additivity under oxygenated or hypoxic conditions
divided by the surviving fraction of mitomycin
C+Pt complex observed experimentally under
oxygenated or hypoxic conditions.
Results
The potential of cis-diamminedichloroplatinum(II)
(CDDP), trans-di(2-nitroimidazole)dichloro-
platinum(II) (NIPt), trans-di(2-amino-5-nitro-
thiazole)dichloroplatinum(II) (Plant), (1,2-diamino-
4-nitrobenzene)dichloroplatinum(II) (Plato), and
cis-dipyridinedichloroplatinum(II) to act as chemo-
potentiators of mitomycin C cytotoxicity toward
EMT6 mouse mammary carcinoma cells in vitro
under oxygenated and hypoxic conditions has been
assessed (Table I). The two concentrations of each
platinum complex, 0.1 and 0.01 M, selected for
testing in combination with mitomycin C were
chosen because these doses are either non-toxic
or only slightly cytotoxic alone. Plasma levels of
195mPt in patients given a standard clinical dose of
cis-diamminedichloroplatinum(II) are -1 Mm of the
drug 4-8h after administration (Lange et al., 1973).
Similarly, the concentrations of mitomycin C
selected for study, that is 1, 0.1 and 0.01 Mm, are in
the range of clinically achievable serum concentra-
tions of the drug (Fujita, 1971; Hartigh, 1983).
Isobolograms prepared by the method of Deen &
Williams (1979) for combinations of CDDP and
mitomycinC areshowninFigure 1. Underoxygenated
conditions the combination with 0.1 Mm CDDP
gave subadditive results with 0.01 gM mitomycin C,
additive results with 0.1 Mm mitomycin C and 2.2-
fold enhancement over additivity at 1 gM mitomycin
C. With the lower concentration of CDDP under
oxygenated conditions, there was an enhancement in
cell killing of - 3-fold over that expected for
additivity at each of the mitomycin C concen-
trations. Under hypoxic conditions in combination
with 0.1 Mm CDDP, however, much greater poten-
tiation of the mitomycin C cytotoxicity occurred.
There was a 5-fold enhancement at 1 gM mitomycin
C, a 20-fold enhancement at 0.1 Mm mitomycin C
and a 60-fold enhancement at 0.01 gM mitomycin
C. With the lower concentration of CDDP under
hypoxic conditions there was a 3-fold potentiation
ofmitomycin C toxicity at drug concentrations of 1
and 0.1 Mm and a 6-fold enhancement of mitomycin
C cytotoxicity at a drug concentration of 0.01 gM.
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platinum (II) conplexes.
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Figure 1 Isobolograms for CDDP held constant at
0.1 or 0.01 m in combination with mitomycin C (1,0.1
and 0.01 M) under oxygenated and hypoxic
conditions. The upper dashed line is the dose reponse
curve for mitomycin C alone. The solid and dotted
lines form the envelope of additivity. The points (@)
indicated are the experimental results for the drug
combination. The experiment was repeated 3 times. (a)
oxic, 0.1 iM CDDP; (b) oxic, 0.01FM CDDP; (c)
hypoxic 0.1 M CDDP; (d) hypoxic 0.01 M CDDP.
Isobolograms for combinations of NIPt with
mitomycin C are shown in Figure 2. Since NIPt at
0.1 and 0.01Mm is non-toxic to both oxygenated
and hypoxic cells under the conditions of these
experiments, the isobologram envelopes of
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Figure 2 Isobolograms for NIPt held constant at 0.1
or 0.01 IM in combination with mitomycin C (1,0.1 or
0.01 jiM) under oxygenated and hypoxic conditions.
The upper dashed line is the dose response curve for
mitomycin C alone. The solid and dotted lines form
the envelope of additivity. The points (0) indicated
are the experimental results for the drug combination.
The experiment was repeated 3 times. (a) oxic, 0.1juM
NIPt; (b) oxic, 0.01 pM NIPt; (c) hypoxic, 0.1 gM NIPt;
(d) hypoxic, 0.01 gM NIPt.
additivity collapse to single lines. Under oxygenated
conditions 0.1 M NIPt enhanced the cytotoxicity of
mitomycin C 4-7-fold, however 0.01 gM NIPt
produced almost no effect on mitomycin C
cytotoxicity resulting in enhancements of 1.5-1.75-
fold. Under hypoxic conditions, the combinations
of 0.1 M NIPt and 1 gM mitomycin C was 40 times
more cytotoxic than expected for strict additivity,
0.1 jIM NIPt and 0.1 M mitomycin C was 60 times
more cytotoxic than expected, and 0.1 uM NIPt and
0.01 juM mitomycin C was 30 times more cytotoxic
than expected for strict additivity. With 0.01 OM
NIPt, under hypoxic conditions there was 15-20-
fold enhancement in cell killing over that expected
for additivity over the range of mitomycin C
concentrations examined.
Under oxygenated conditions both 0.1 and
0.01 gM Plant enhanced the cytotoxicity of each
concentration of mitomycin C approximately 2.5-
fold, as shown in Figure 3. There was 5 times more
cell killing than expected for 1 gM mitomycin C, 14
times more cell killing than expected for 0.1 M
mitomycin C and 7 times more cell killing than
expected for 0.01 gM mitomycin C. At the lower
concentration of Plant, there was a 3-fold
potentiation of mitomycin C cytotoxicity at 1 M
concentration of the drug and a 6-fold potentiation
of mitomycin C cytotoxicity at 0.1 and 0.01 JUM
concentration.
Figure 3 Isobolograms for Plant held constant at 0.1
or 0.01yM in combination with mitomycin C (1,0.1
and 0.01 pM) under oxygenated and hypoxic
conditions. The upper dashed line is the dose response
curve for mitomycin C alone. The solid and dotted
lines form the envelope of additivity. The points (0)
indicated are the experimental results for the drug
combination. The experiment was repeated 3 times. (a)
oxic, 0.1 M Plant; (b) oxic 0.01 pM Plant; (c) hypoxic,
0.1 pM Plant; (d) hypoxic, 0.01 jIM Plant.
Isobolograms for combinations of Plato with
mitomycin C are shown in Figure 4. At both 0.1
and 0.01 gM Plato the cytotoxicity of mitomycin C
at all of the concentrations examined was
approximately 3.3-fold greater than additive in
oxygenated cells. Under hypoxic conditions the
combination of 0.1 M Plato land 1 gM mitomycin
C was 30-fold more cytotoxic than expected for
additivity. With 0.1JM mitomycin C the
combination was 50-fold more cytotoxic than
expected for additivity and with 0.01 gM mitomycin
C the combination was 60-fold more cytotoxic than
expected for additivity. At the lower concentration
of Plato in combination with 1 M mitomycin C
there was a 16-fold enhancement in cytotoxicity
with 0.1 M mitomycin C there was a 3-fold
enhancement in cytotoxicity and with 0.01 gM
mitomycin C there was an 8-fold enhancement on
cytotoxicity.
The results for combinations of PyPt and
mitomycin C are shown as isobolograms in Figure
5. Under oxygenated conditions PyPt at both 0.1
and 0.01 pM was essentially additive. However,
under hypoxic conditions 0.1 pM PyPt in
combination with 1 gM mitomycin C was 40-fold
more cytotoxic than expected from additivity. At
0.1 and 0.O1pM mitomycin C in combination with
0.1 M PyPt there was 8-fold and 14-fold
enhancement of cytotoxicity over that expected for
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Figure 4 Isobolograms for Plato held constant at 0.1
or 0.01/IM in combination with mitomycin C (1,0.1
and 0.01 pM) under oxygenated and hypoxic
conditions. The upper dashed line is the dose response
curve for mitomycin C alone. The solid and dotted
lines form the envelope of additivity. The points (0)
indicated are the experimental results for the drug
combination. The experiment was repeated 3 times. (a)
oxic, 0.1 gm Plato; (b) oxic, 0.01 pM Plato; (c) hypoxic,
0.1 m Plato; (d) hypoxic, 0.01 pm Plato.
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Figure 5 Isobolograms for PyPt held constant at 0.1
or 0.01gM in combination with mitomycin C (1,0.1,
and 0.01gM) under oxygenated and hypoxic
conditions. The upper dashed line is the dose reponse
curve for mitomycin C alone. The solid and dotted
lines form the envelope of additivity. The points (0)
indicated are the experimental results for the drug
combination. The experiment was repeated 3 times.
(a) oxic, 0.1 M PyPt: (b) oxic, 0.01 M PyPt; (c) hypoxic,
0.1 gM PyPt; (d) 0.01 M PyPt.
additivity. At the lower concentration of PyPt,
overall the combinations with mitomycin C
produced cytotoxicity 5 times greater than expected
from additivity of the cytotoxicity of the individual
agents.
When the organic ligands, that is 2-nitro-
imidazole, 2-amino-5-nitrothiazole, 1,2-diamino-4-
nitrobenzene, and pyridine, were tested for their
ability to enhance the cytotoxicity of mitomycin C
under oxygenated and hypoxic conditions the
following effects were observed. 2-nitroimidazole
at 0.1 M had no effect on mitomycin C cyto-
toxicity under oxygenated or hypoxic conditions.
With 0.1 gUM 2-amino-5-nitrothiazole under
oxygenated conditions there was a 3.5-fold enhance-
ment ofmitomycin C cytotoxicity and under hypoxic
conditions there was a 2-fold enhancement in
mitomycin C cytotoxicity at all of the concen-
trations of mitomycin C examined. Using 1,2-
diamino-4-nitrobenzene at 0.1 uM under oxy-
genated conditions there was a 1.5-2-fold
enhancement of mitomycin C cytotoxicity at each
of the three concentrations of mitomycin C
examined and under hypoxic conditions there was a
4-5-fold enhancement of mitomycin C cytotoxicity
at each of the three concentrations of mitomycin C
examined. Pyridine at 0.1jIM had no effect on
mitomycin C cytotoxicity under oxygenated or
hypoxic incubation conditions.
Discussion
Cis-diamminedichloroplatinum(II) has shown a
broad spectrum of clinical activity. A number of
combination chemotherapy regimens including
cis-diamminedichloroplatinum(II) have been
successfully developed for all of these tumour types
and additional trials are ongoing to confirm the
data and to assess the role of each of the individual
components in these combinations (Burchenal et
al., 1979). Analogs of CDDP are sought to enlarge
the spectrum of activity, increase selectivity, and
diminish toxicity (Rose et al., 1982).
Hypoxic cells form a therapeutically resistant
subpopulation in solid tumours. Nitroaromatic
compounds of a variety of structures have been
shown to be more cytotoxic toward hypoxic cells in
culture than toward well oxygenated cells. The
rationale for the selection of each of the organic
ligands in the platinum complexes in the present
study was: (i) 2-nitroimidazole is the nitroaromatic
heterocyclic moiety of misonidazole, (ii) 2-amino-5-
nitrothiazole, has been shown to be a hypoxic cell
radiosensitizer both in vitro and in vivo (Rockwell,
1978; Rockwell et al., 1982); (iii) 1, 2-diamino cyclic
complexes of platinum appear to be interesting
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clinically (Burchenal et al., 1979; Hill et al., 1979;
Rose et al., 1982), and the 1, 2-diamino-4-nitro-
benzene derivative of platinum incorporates a 1,2-
diamino ring system and a 4-nitrobenzene group
which is a potential hypoxic cell radiosensitizing
moiety. Cis-dipyridinedichloroplatinum is a well-
known neutral complex of platinum. Preincubation
of cells under hypoxic conditions with 5mM
misonidazole sensitizes them to subsequent
treatment under aerobic conditions with several
cytotoxic drugs (mostly alkylating agents and
nitrosoureas) but protects against adriamycin and
mAMSA. Experiments do not previously appear to
have been carried out in which the cytotoxic drug
exposure following pre-incubation has also been
performed under hypoxic conditions.
Although mitomycin C is selectively cytotoxic
toward hypoxic cells; the considerable cytotoxicity
of this agent to oxygenated cells makes it difficult
to take advantage of this hypoxic cell selectivity in
the clinic. Several chemotherapeutic approaches to
the hypoxic cell problem are possible, we believe
that Tesearch into the development of drugs which
are selectively cytotoxic toward hypoxic cells is
important (Rauth et al., 1983; Teicher et al., 1981).
Our current results suggest that the selectivity of
mitomycin C for hypoxic cells can be very
substantially enhanced by the combination of
mitomycin C treatment with non-toxic or slightly
toxic levels of a variety of platinum complexes.
Overall, the two most effective chemopotentiators
of mitomycin C cytotoxicity toward hypoxic cells
were NIPt and Plato. The dipyridine platinum
complex and the 2-amino-5-nitrothiazole platinum
complex were somewhat less effective chemo-
potentiators. Studies are underway to examine this
effect in vivo.
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